Targeted Therapy to Reduce Relapse of Pediatric Leukemia
Files
Download Transcript, Episode 127 (64 KB)
Loading...
Document Type
Podcast
Hosts
Michael Smith
Featured Speaker
John Perry, PhD
Length of Episode
11:08
Description
Patients that have residual leukemia stem cells after chemotherapy and other treatments have substantially higher risk for relapse. Survival rates for relapsed leukemia are very poor. Even when patients survive long-term, the very toxic anti-cancer treatments are escalated in treating relapsed leukemia. This particularly risks long-term health and substantially increases the risk of early death due to side-effects of the treatment itself.
John Perry, PhD, faculty member of the Children's Research Institute at Children's Mercy Kansas City is studying how leukemia stem cells resist current anti-cancer treatments.
Join us for this podcast as Dr. Perry discusses the promise of low-dose doxorubicin as a targeted therapy against leukemia stem cells rather than a broadly toxic chemotherapy drug.
Publication Date
12-10-2018
Recommended Citation
Smith, Michael and Perry, John M., "Targeted Therapy to Reduce Relapse of Pediatric Leukemia" (2018). Transformational Pediatrics Podcast. 127.
https://scholarlyexchange.childrensmercy.org/transformational-peds_podcast/127
